ChloroquineV1, PubMed, Corpus, bibRecord, 000103

Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Identifieur interne : 000103 ( PubMed/Corpus ); précédent : 000102; suivant : 000104

Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Source :

Annals of translational medicine [ 2305-5839 ] ; 2018.

RBID : pubmed:29862243

Abstract

It is now widely accepted that long-term aminoquinoline antimalarial therapy with hydroxychloroquine (HCQ) can mitigate one of the most important comorbidities of systemic lupus erythematosus (LE)-atherosclerotic cardiovascular disease (ASCVD). Increasing evidence suggests that idiopathic inflammatory myopathy (IIM) patients have a risk for ASCVD comorbidity that is similar to that of systemic LE. I would like to explore the primary hypothesis that long-term HCQ therapy could provide those with IIM, especially dermatomyositis (DM) patients, an ASCVD comorbidity benefit similar to that of systemic LE. In addition, while HCQ is known to have clinical benefits for the cutaneous manifestations of DM, I would also like to explore the secondary hypothesis that HCQ might have steroid-sparing effects on one or more of the systemic manifestations of DM.

DOI: 10.21037/atm.2018.03.05
PubMed: 29862243

Links to Exploration step

pubmed:29862243

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?</title>
<author><name sortKey="Sontheimer, Richard D" sort="Sontheimer, Richard D" uniqKey="Sontheimer R" first="Richard D" last="Sontheimer">Richard D. Sontheimer</name>
<affiliation><nlm:affiliation>Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29862243</idno>
<idno type="pmid">29862243</idno>
<idno type="doi">10.21037/atm.2018.03.05</idno>
<idno type="wicri:Area/PubMed/Corpus">000103</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000103</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?</title>
<author><name sortKey="Sontheimer, Richard D" sort="Sontheimer, Richard D" uniqKey="Sontheimer R" first="Richard D" last="Sontheimer">Richard D. Sontheimer</name>
<affiliation><nlm:affiliation>Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of translational medicine</title>
<idno type="ISSN">2305-5839</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">It is now widely accepted that long-term aminoquinoline antimalarial therapy with hydroxychloroquine (HCQ) can mitigate one of the most important comorbidities of systemic lupus erythematosus (LE)-atherosclerotic cardiovascular disease (ASCVD). Increasing evidence suggests that idiopathic inflammatory myopathy (IIM) patients have a risk for ASCVD comorbidity that is similar to that of systemic LE. I would like to explore the primary hypothesis that long-term HCQ therapy could provide those with IIM, especially dermatomyositis (DM) patients, an ASCVD comorbidity benefit similar to that of systemic LE. In addition, while HCQ is known to have clinical benefits for the cutaneous manifestations of DM, I would also like to explore the secondary hypothesis that HCQ might have steroid-sparing effects on one or more of the systemic manifestations of DM.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29862243</PMID>
<DateRevised><Year>2019</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">2305-5839</ISSN>
<JournalIssue CitedMedium="Print"><Volume>6</Volume>
<Issue>8</Issue>
<PubDate><Year>2018</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Annals of translational medicine</Title>
<ISOAbbreviation>Ann Transl Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?</ArticleTitle>
<Pagination><MedlinePgn>154</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.21037/atm.2018.03.05</ELocationID>
<Abstract><AbstractText>It is now widely accepted that long-term aminoquinoline antimalarial therapy with hydroxychloroquine (HCQ) can mitigate one of the most important comorbidities of systemic lupus erythematosus (LE)-atherosclerotic cardiovascular disease (ASCVD). Increasing evidence suggests that idiopathic inflammatory myopathy (IIM) patients have a risk for ASCVD comorbidity that is similar to that of systemic LE. I would like to explore the primary hypothesis that long-term HCQ therapy could provide those with IIM, especially dermatomyositis (DM) patients, an ASCVD comorbidity benefit similar to that of systemic LE. In addition, while HCQ is known to have clinical benefits for the cutaneous manifestations of DM, I would also like to explore the secondary hypothesis that HCQ might have steroid-sparing effects on one or more of the systemic manifestations of DM.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sontheimer</LastName>
<ForeName>Richard D</ForeName>
<Initials>RD</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Ann Transl Med</MedlineTA>
<NlmUniqueID>101617978</NlmUniqueID>
<ISSNLinking>2305-5839</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aminoquinoline antimalarials, atherosclerotic cardiovascular disease (ASCVD)</Keyword>
<Keyword MajorTopicYN="N">comorbidities, dermatomyositis (DM)</Keyword>
<Keyword MajorTopicYN="N">hydroxychloroquine (HCQ)</Keyword>
<Keyword MajorTopicYN="N">idiopathic inflammatory myopathies (IIM)</Keyword>
<Keyword MajorTopicYN="N">interstitial lung disease (ILD)</Keyword>
<Keyword MajorTopicYN="N">lupus erythematosus (LE)</Keyword>
<Keyword MajorTopicYN="N">quinacrine</Keyword>
</KeywordList>
<CoiStatement>Conflicts of Interest: The author has no conflicts of interest to declare.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29862243</ArticleId>
<ArticleId IdType="doi">10.21037/atm.2018.03.05</ArticleId>
<ArticleId IdType="pii">atm-06-08-154</ArticleId>
<ArticleId IdType="pmc">PMC5952016</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Arch Dermatol. 2002 Sep;138(9):1231-3; discussion 1233</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12224986</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Transl Med. 2017 Apr;5(7):160</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28480196</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2017 Sep 11;:null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28901270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>RMD Open. 2016 Sep 27;2(2):e000291</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27752355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2015 Sep;82(3):199-207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26099519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2018 Jan;78(1):107-114.e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29061479</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2018 Apr 1;57(4):694-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29373707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 1985 Dec;12(6):1214-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4093940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Res Ther. 2011;13(6):249</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22192711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 2017 Jul;44(7):1032-1038</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28507183</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Rheum Dis. 2015 Nov;18(8):818-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26385431</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2017 Aug;77(2):374-377</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28711090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Investig Dermatol Symp Proc. 2017 Oct;18(2):S57-S63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28941496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Clin Immunol. 2017 Aug;13(8):753-768</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28471690</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 1989 Dec;16(12):1545-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2483176</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Autoimmun. 2016 Nov;74:73-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27371107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Rev Allergy Immunol. 2017 Feb;52(1):58-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26780034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(1):e29161</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22235269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Womens Dermatol. 2017 Jun 13;3(4):189-194</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29234712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Dermatol. 2005 Jul;141(7):855-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16027300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2018 Jan;78(1):100-106.e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28989103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Immun. 2012 Apr;13(3):207-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21881594</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2016 Mar;55(3):461-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26424835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Res Ther. 2013 Jan 08;15(1):R7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23298514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2017 Jan 14;68:317-330</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27813878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 1994 Nov;21(11):2171-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7726968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Presse Med. 2011 Apr;40(4 Pt 2):e209-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21376512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 1984 Apr;10(4):592-600</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6715608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Feb 04;6:20303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26842423</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000103 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000103 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:29862243
   |texte=   Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:29862243" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki